Experimental & Molecular Medicine (EMM) is Koreas first biochemistry journal and is relaunched as an Open Access, fully peer-reviewed international journal devoted to publishing the latest and most important advances in genetic, molecular and cellular studies of human physiology and diseases. The journal aims to communicate the improved clinical benefits for human health from the experimental and translational research performed using molecular tools. Areas that are covered include, but are not limited to, cancer biology, immunology, neuroscience, cardiovascular diseases, genetics and genomics, gene therapy and stem cells and regenerative medicine.

In March 2014, EMM published a special feature on Mucosal Immunity and Vaccines with a series of reviews providing an overview of current understanding in this area and covering a range of key topics including regulatory T cell vaccination, antigen targeting to M cells, mucosal mast cells and the role mucosal dendritic cells play in shaping mucosal immunity.

Volume 47, February 2015 ISSN (online): 2092-6413

2013 Impact Factor 2.462* 54/122 Medicine, Research & Experimental 176/291 Biochemistry & Molecular Biology

Editor-in-Chief: Dae-Myung Jue

*2013 Journal Citation Reports Science Edition (Thomson Reuters, 2014)

A key regulatory protein provides a potential new therapeutic target for difficult-to-treat breast cancer. Around 10-20% of breast cancers are known as triple-negative because they don't show any of the three markers commonly found in breast cancer cells and don't respond well to common therapies. A team led by Yeon-Sun Seong and Insoo Bae from Dankook University in South Korea and Georgetown Univiersity in U.S. treated triple-negative breast cancer cells with PI-103, a drug known to block a key pathway regulating cell division and tumor formation. The researchers observed a decrease in the expression of -TrCP1, a subunit of a larger protein complex involved in ubiquitin proteasome pathway. Experimentally reducing levels of -TrCP1 was sufficient to slow the growth of the breast cancer cells. These results raise the possibility of inhibiting -TrCP1 in novel ways to combat triple-negative breast cancer.

An anti-rheumatic drug can protect hearing in mice from the damage wrought by platinum-containing chemotherapeutic agents. A research team led by Raekil Park of the Wonkwang University College of Medicine in Iksan, South Korea, investigated whether bucillamine, a drug used to treat rheumatoid arthritis, can lessen the degree of hearing loss caused by the cancer chemotherapy drug cisplatin. In cisplatin-treated mice, bucillamine led to better scores on a standard hearing test. Bucillamine also reduced cisplatin-induced sensory hair cell loss in cochlear explants grown in a lab dish. The researchers analyzed the molecular response using a mouse auditory cell line treated with cisplatin. They observed that bucillamine lowered the activity of proteins involved in cell death, suppressed the generation of damaging free radicals, and increased the expression of various proteins involved in detoxification.

Special Feature on Epstein-Barr Virus (EBV)

It has been 50 years since Michael Anthony Epstein and Yvonne Barr discovered Epstein-Barr Virus (EBV) particles in cell lines cultured from tumor tissue from a Burkitt lymphoma. Since the initial discovery of the virus, more than 20,000 scientific papers on the characteristics, functions and oncogenic mechanisms of viral genes, the spectrum of EBV-associated diseases, and treatment of patients have been published. Experimental & Molecular Medicine contains six review articles that provide an overview of our current understanding of Epstein-Barr virology and oncogenesis and of EBV-associated neoplasm.

Original post:

Experimental & Molecular Medicine - Nature Publishing ...